Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Clinical Microbiology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
LETTERS TO THE EDITOR

De Novo Daptomycin Nonsusceptibility in a Clinical Isolate

Emil P. Lesho, Glenn W. Wortmann, David Craft, Kimberly A. Moran
Emil P. Lesho
Walter Reed Army Medical Center 6900 Georgia Ave., N.W. Washington, D.C. 20307
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Emil.Lesho@NA.amedd.army.mil
Glenn W. Wortmann
Walter Reed Army Medical Center 6900 Georgia Ave., N.W. Washington, D.C. 20307
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Craft
Walter Reed Army Medical Center 6900 Georgia Ave., N.W. Washington, D.C. 20307
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kimberly A. Moran
Walter Reed Army Medical Center 6900 Georgia Ave., N.W. Washington, D.C. 20307
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/JCM.44.2.673.2006
  • Article
  • Info & Metrics
  • PDF
Loading

We report a case of non-daptomycin-susceptible Enterococcus faecium bloodstream infection in a patient with no previous exposure to daptomycin. To our knowledge, this is the first report of de novo resistance to daptomycin in a clinical isolate.

An 84-year-old man was admitted to the hospital because of progressively debilitating weakness and fever. A past medical history of chronic renal insufficiency, compensated congestive heart failure, urinary incontinence, and anemia was elicited. Physical examination findings included a nonradiating systolic heart murmur and mild pitting edema in both lower extremities. There were no skin lesions or rashes and no stigmata of endocarditis. Serum bicarbonate, creatinine, and hematocrit were 19 mmol/liter, 3.2 mg/dl, and 32.5%, respectively. The remainder of his complete blood count and chemistry panel results were normal. Blood cultures were positive for vancomycin-resistant Enterococcus faecium and Enterococcus gallinarum. An echocardiogram revealed echogenic material on the aortic valve consistent with the presence of a vegetation.

Laboratory tests of an E. faecium isolate revealed a MIC for daptomycin as determined by an Epsilometer test (AB Biodisk, Sweden) of 6 μg/ml (a result indicating nonsusceptibility according to the susceptibility breakpoint of ≤4 μg/ml listed in the product package insert). The Epsilometer test was repeated and gave a result of 4 μg/ml. The E. faecium isolate was also resistant to penicillin, ampicillin, gentamicin, and vancomycin but was susceptible to linezolid. The E. gallinarum isolate was susceptible to ampicillin, gentamicin, and vancomycin and was not tested for susceptibility to daptomycin.

Options for treating vancomycin-resistant enterococcal infections remain limited. Promising alternatives include treatment with daptomycin, linezolid, and quinupristin-dalfopristin (for E. faecium only). Daptomycin is considered by many to be an attractive alternative to linezolid and quinupristin-dalfopristin (3, 6). Daptomycin in this patient would have been preferred due to its rapid bactericidal activity, cost considerations, and the absence of the bone marrow suppression that may be seen with linezolid (particularly associated with the longer duration of therapy needed for endocarditis) and because of once-daily dosing. Additionally, compared to linezolid there may be a lesser tendency for the accumulation of potentially harmful metabolites in the setting of renal failure (1).

Based on the recent introduction of daptomycin and the paucity of reports, the development of resistance to this drug in enterococci appears to be rare. Furthermore, spontaneous resistance in an isolate with no preceding exposure to daptomycin has not been previously reported, although there have been four recent reports of emerging daptomycin resistance (3, 4, 5, 7), one involved methicillin-resistant Staphylococcus aureus; all of the cases were associated with prolonged treatment with daptomycin. In a recent review of the world literature on vancomycin-resistant enterococcal endocarditis, (8) there were no instances or reports of daptomycin-resistant native or prosthetic valve endocarditis (8).

A unique aspect of the present case is that the patient had no previous exposure to daptomycin. Additionally, there were no risks known to be associated with the development of multidrug-resistant enterococcal infection, such as longer duration of hospitalization, prolonged stay in an intensive care unit, high APACHE II score, excessive exposure to vancomycin and other antibiotics, repeated abdominal surgeries, and immunosuppression associated with organ transplantation or hematologic malignancy (2, 9). There have been no previous reports of clinical enterococcal isolates initially nonsusceptible to daptomycin at our institution or, to our knowledge, in our community. We are hopeful that this case is not a harbinger of an emerging pattern.

  • Copyright © 2006 American Society for Microbiology

REFERENCES

  1. 1.↵
    Anonymous. Linezolid (Zyvox) package insert LAB 0139-10.0, revised May 2005. Pharmacia & Upjohn, Division of Pfizer Inc., New York, N.Y.
  2. 2.↵
    Edmond, M. B., J. F. Ober, D. L. Weinbaum, et al. 1995. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin. Infect. Dis.20:1126-1133.
    OpenUrlPubMed
  3. 3.↵
    Mangili, A., I. Bica, D. R. Snydman, and D. H. Hamer. 2005. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis.40:1058-1060.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    Munoz-Price, L. S., K. Lolans, and J. P. Quinn. 2005. Emergence of resistance to daptomycin during treatment of vancomycin resistant Enterococcus faecalis infection. Clin. Infect. Dis.41:565-566.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    Sabol, K., J. E. Patterson, J. S. Lewis, A. Owens, J. Cadena, and J. H. Jorgensen. 2005. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob. Agents Chemother.49:1664-1665.
    OpenUrlFREE Full Text
  6. 6.↵
    Segreti, J. 11 May 2005, posting date. Efficacy of current agents used in the treatment of gram-positive infections and the consequences of resistance. Clin. Microbiol. Infect. (Suppl. 3):29-35. [Online.]
    OpenUrl
  7. 7.↵
    Silverman, J. A., N. Oliver, T. Andrew, and T. Li. 2001. Resistance studies with daptomycin. Antimicrob. Agents Chemother.45:1799-1802.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    Stevens, M. P., and M. B. Edmond. 2005. Endocarditis due to vancomycin-resistant enterococci: case report and review of the literature. Clin. Infect. Dis.41:1134-1142.
    OpenUrlCrossRefPubMed
  9. 9.↵
    Tonieporth, N. G., R. B. Roberts, J. Joylene, A. Hafner, and L. W. Riley. 1996. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin. Infect. Dis.23:767-772.
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Download PDF
Citation Tools
De Novo Daptomycin Nonsusceptibility in a Clinical Isolate
Emil P. Lesho, Glenn W. Wortmann, David Craft, Kimberly A. Moran
Journal of Clinical Microbiology Feb 2006, 44 (2) 673; DOI: 10.1128/JCM.44.2.673.2006

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Clinical Microbiology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
De Novo Daptomycin Nonsusceptibility in a Clinical Isolate
(Your Name) has forwarded a page to you from Journal of Clinical Microbiology
(Your Name) thought you would be interested in this article in Journal of Clinical Microbiology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
De Novo Daptomycin Nonsusceptibility in a Clinical Isolate
Emil P. Lesho, Glenn W. Wortmann, David Craft, Kimberly A. Moran
Journal of Clinical Microbiology Feb 2006, 44 (2) 673; DOI: 10.1128/JCM.44.2.673.2006
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • REFERENCES
  • Info & Metrics
  • PDF

KEYWORDS

Anti-Bacterial Agents
bacteremia
daptomycin
Drug Resistance, Bacterial
Gram-Positive Bacterial Infections

Related Articles

Cited By...

About

  • About JCM
  • Editor in Chief
  • Board of Editors
  • Editor Conflicts of Interest
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Resources for Clinical Microbiologists
  • Ethics
  • Contact Us

Follow #JClinMicro

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

 

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0095-1137; Online ISSN: 1098-660X